Telehealth TRT can sit on the same storefront, patient portal and billing your GLP-1 brand already runs. Testosterone adds its own lane: DEA-registered prescribers, a live video visit, labs before any prescription, refill caps and a controlled-substance pharmacy. FUSE runs both lanes behind one brand.
Telehealth TRT is the second program most GLP-1 brands get asked about, and the biggest name in the category just made that official. On October 21, 2026, Hims launched injectable and oral TRT and said testosterone had been scaling faster than any other specialty outside weight loss, only three quarters after it launched. The men that launch was built for are the same men already paying you every month for semaglutide or tirzepatide.
So you start pricing it out, and the quotes come back as a whole second stack: a TRT platform, a prescriber group with DEA registrations, a controlled-substance pharmacy and a lab partner. That's two contracts, two patient logins and two places for a refill to break. Here's what testosterone really changes, what carries over from GLP-1, and how to add both without a second vendor.
Executive Summary
GLP-1 brands can add TRT and HRT without a second vendor because most of the stack carries over: storefront, intake engine, portal, payments and refills. Testosterone is the one product with federal controlled-substance rules, so telehealth TRT runs in its own lane with DEA-registered prescribers, a video visit, repeat morning labs, a five-refill cap and a DEA-registered pharmacy. Estrogen and progesterone skip the DEA layer. On FUSE, both lanes run behind one brand at published prices, and the DEA rule behind remote testosterone prescribing runs through December 31, 2026.
Why GLP-1 Brands Are Adding Telehealth TRT
Your GLP-1 members are already the TRT audience
Epic Research tracked 109 million men and found the share with an active testosterone prescription fell from 0.83% in 2013 to 0.64% in 2021, then climbed back to 0.93% in 2025 and 0.95% in early 2026. Men aged 50 to 64 had the highest rate at 1.57%, with men 40 to 49 close behind at 1.35%. If your GLP-1 list skews toward men in their 40s and 50s, you're already sitting on the group with the highest prescribing rates.
You've probably seen it in your own inbox too. One men's health brand on FUSE with a 120,000-subscriber list noticed testosterone content kept beating its normal open rates, and that's what pushed it to launch TRT.
Why the second vendor quote shows up
A GLP-1 stack is built for non-controlled prescribing. Semaglutide and tirzepatide aren't scheduled drugs, so nothing in that workflow ever had to handle DEA rules. Once testosterone enters the catalog, every missing piece gets quoted as a separate telehealth TRT package.
Key insight: Even Hims, which runs most of its intake online, has a licensed provider review symptoms, history and lab results in a live visit before any testosterone is prescribed. The video step belongs to the testosterone lane at every scale.
What Telehealth TRT Changes for a GLP-1 Program
The rules testosterone adds
Testosterone is a Schedule III controlled substance, and that one fact drives most of the rows below.
| Requirement | GLP-1 lane | TRT lane |
|---|---|---|
| Drug status | Not controlled | Schedule III |
| Visit type | Async where the state allows | Audio-video visit |
| Prescriber | State license | State license plus DEA registration |
| Refills | Set by the provider | Five refills within six months, max |
| Pharmacy | Licensed in the patient's state | Also DEA-registered |
| Labs | Provider's call | Repeat morning testosterone tests |
The visit rule comes from the DEA's fourth temporary extension, which lets DEA-registered practitioners prescribe Schedule II through V drugs over audio-video telemedicine without a prior in-person exam through December 31, 2026. The refill cap sits in 21 CFR 1306.22, so after five refills or six months the provider writes a new prescription. The lab step follows the Endocrine Society guideline, which confirms low testosterone with a repeat fasting morning test before diagnosis.
Where estrogen and progesterone HRT fit
Estrogen and progesterone aren't controlled substances, so they follow the same state-law path as your GLP-1 program. That gives you a sequencing choice: open HRT for women first, since it has no DEA dependency, and add testosterone once your video and pharmacy setup is confirmed. Our perimenopause programs use case covers that lane.
What Stays the Same When You Add TRT and HRT
The parts your GLP-1 program already runs
Most of what you built for GLP-1 carries straight into a hormone lane:
- Your storefront, domain and brand, with one login and one order history per patient.
- Stripe billing, subscriptions and failed-payment retries.
- Refill reminders and the dashboard you use to track approvals, declines and churn.
- Your LegitScript certification, which you update with the new service instead of reapplying.
The parts that need their own lane
Telehealth TRT needs its own landing page and intake. A weight-loss intake asks about weight history and GLP-1 contraindications, while a hormone intake asks about fertility plans, prior hormone use and cardiac history, and the provider needs those question sets kept apart. You'll also need a video visit booked after labs, plus messages that keep patients moving while results are pending. Inside your GLP-1 program, the cross-sell should read as an invitation to a hormone evaluation, since only the provider decides who gets a prescription.
How to Start a TRT Clinic Lane Inside Your GLP-1 Brand
Six steps from decision to first TRT patient
Our TRT clinic guide covers a build from zero. For a live GLP-1 brand, the order looks like this:
- Map your launch states. FUSE confirms controlled-substance prescriber and pharmacy coverage for each state before you design the program.
- Switch on the testosterone program in your FUSE catalog and set your retail price.
- Build the hormone evaluation page and intake, separate from your weight-loss funnel.
- Configure labs and the video visit so results reach the provider before the live consult.
- Tie refills to lab review, with a new prescription request at the five-refill or six-month mark.
- Update your LegitScript scope before running any TRT ads.
What a live telehealth TRT launch looks like
That men's health brand launched TRT on FUSE in eight weeks, credentialing and lab integration included. Refills were tied to lab review cadence, and FUSE reports its subscription retention came in above DTC health benchmarks. A regional lab brand went live with a hormone program in six weeks after starting with one program instead of three.
What a TRT and HRT Lane Costs on FUSE
Platform pricing doesn't change per program
FUSE's published pricing is set by plan, not by program. Growth is $5,600 upfront, covering expedited LegitScript coordination and your first month, then $699 a month. Partner is $30,000 for onboarding with 12 months included, then $3,000 a month from month 13. The merchant fee is 3% on DIY and 2% on Growth and Partner, with no per-visit or per-prescription fees. Clinical, pharmacy and lab costs show up before you commit.
Year-one math for a GLP-1 brand adding TRT
Say you run a GLP-1 brand in Dallas on Growth. Year one is $5,600 plus 11 months at $699, or $13,289 in platform fees, and that number stays put when you switch on TRT and HRT. A Boston brand pays the same, though its state map will differ. On the revenue side, TRT Nation lists $99 a month for medication and provider visits plus a $129 lab panel, so at that price the 2% fee is about $1.98 per member each month.
How to Keep Telehealth TRT Compliant as It Grows
Marketing claims for the testosterone lane
Keep weight-loss claims on the GLP-1 page. The Endocrine Society guideline recommends against testosterone as a way to improve glycemic control in men with type 2 diabetes, so an ad pairing testosterone with weight or blood sugar outcomes puts your LegitScript standing at risk. Hormone creative should invite men with symptoms to an evaluation and say plainly that labs come first. Our LegitScript guide covers how those claims get reviewed.
A plan for December 31, 2026
The DEA extension behind remote testosterone prescribing ends on December 31, 2026. DEA sent its final special registration rule to White House review on August 25, 2026, and the text still isn't public. Build your telehealth TRT lane so a rule change becomes a settings update: keep video encounter records clean, know which patients have had an in-person evaluation, and write down a plan for active patients if the rules shift.
Key insight: Only the testosterone line depends on that DEA date. Your GLP-1 program and any estrogen or progesterone HRT keep running whatever the DEA decides.
Adding TRT and HRT to Your GLP-1 Brand With FUSE
Your GLP-1 members already trust you with a monthly routine, and more of them are asking about testosterone. FUSE puts telehealth TRT, HRT and your GLP-1 program behind one storefront, with independent licensed clinicians making every prescribing decision and pharmacy partners set up for controlled-substance dispensing. You keep the brand, pricing and customer, and you skip the second contract.
Next step: Book a walkthrough with your state list and GLP-1 volume, and we'll map your TRT lane before the December 31 DEA date.
This use case is written for business operators and covers operational and regulatory topics only. It is not medical or legal advice and does not recommend any treatment or dose. Regulatory status was checked on October 29, 2026, so confirm current DEA, state and LegitScript requirements with qualified counsel before launching or changing a program.
References
- Hims & Hers: A New Era for Testosterone Care, Hims Launches New Injectable and Oral TRT Options (October 21, 2026)
- Epic Research: After Nearly a Decade-Long Decrease, Testosterone Prescribing Rates Rising Again (July 29, 2026)
- DEA: DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care (December 31, 2025)
- 21 CFR § 1306.22, Refilling of prescriptions (Legal Information Institute, Cornell Law School)
- Bhasin S et al., Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab (2018)
- Frier Levitt: DEA Telemedicine Special Registration Final Rule Reaches White House Review (October 27, 2026)
- TRT Nation: Testosterone Replacement Therapy pricing
- FUSE Health: How a DTC Brand Added a TRT Revenue Channel at Scale (March 31, 2026)
- FUSE Health: Pricing
Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.
- Background
- Startup Operations & Service Systems
- Experience
- 2x Founder, Multi-Market U.S. Scaling
- Qualifications
- Healthtech Market Expertise & Operational Scaling
- Key Achievement
- Scaled Premier Staff & Eventstaff across major U.S. markets
